Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223378 · ClinicalTrials.gov registry record · Phase 2
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 413
- Enrollment target
NCT01223378: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT01223378 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 413 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (211% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01223378, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 413 participants
- Enrollment target
Study Summary
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
Primary Outcome
Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP) and compared to latanoprost
Interventions
- DRUG Latanoprost
- DRUG BOL-303259-X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2010-12-13 |
| Est. Completion | 2012-06-22 |
| Phase | Phase 2 |
What the finished NCT01223378 record still lists
NCT01223378 is an interventional study that assigns participants to a tested intervention. The registered 413 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (211% higher).
The record links to 0 conditions, and to 2 interventions - of which Latanoprost is the first listed.
NCT01223378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01223378 about?
NCT01223378 is a clinical study titled "Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension". The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
What is the current status of trial NCT01223378?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 413 participants. The study started on 2010-12-13. Estimated completion is 2012-06-22.
What interventions are being tested in trial NCT01223378?
The interventions under investigation include: Latanoprost (DRUG), BOL-303259-X (DRUG).
Who is sponsoring clinical trial NCT01223378?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01223378's enrollment target sits among peer trials
413 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT06792552 · 414 participants · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI